AN2 Therapeutics Appoints New Director, Discloses Officer Compensation
Ticker: ANTX · Form: 8-K · Filed: Nov 5, 2024 · CIK: 1880438
Sentiment: neutral
Topics: board-changes, executive-compensation
TL;DR
AN2 Therapeutics adds a new director, Gaynor, and hints at executive pay changes.
AI Summary
AN2 Therapeutics, Inc. announced on November 4, 2024, a change in its board of directors. Specifically, Dr. Richard S. Gaynor has been appointed as a new director, effective immediately. The company also disclosed compensatory arrangements for certain officers, though specific details of these arrangements were not provided in this filing.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are important for understanding executive incentives.
Risk Assessment
Risk Level: low — This filing primarily concerns board appointments and general disclosures about officer compensation, which are routine corporate events.
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — Registrant
- Richard S. Gaynor (person) — Newly appointed director
- November 4, 2024 (date) — Effective date of director appointment
FAQ
Who has been appointed as a new director to the AN2 Therapeutics board?
Dr. Richard S. Gaynor has been appointed as a new director.
When was the appointment of the new director effective?
The appointment of Dr. Richard S. Gaynor was effective as of November 4, 2024.
What other item is disclosed in this 8-K filing?
The filing also discloses compensatory arrangements of certain officers.
What is the exact name of the registrant?
The exact name of the registrant is AN2 Therapeutics, Inc.
What is the state of incorporation for AN2 Therapeutics, Inc.?
AN2 Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 584 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-11-05 16:05:32
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value ANTX The Nasdaq Global Se
- $450,000 — n received an annual salary increase to $450,000, an option to purchase 63,000 shares of
Filing Documents
- d872811d8k.htm (8-K) — 23KB
- 0001193125-24-251240.txt ( ) — 146KB
- antx-20241104.xsd (EX-101.SCH) — 3KB
- antx-20241104_lab.xml (EX-101.LAB) — 18KB
- antx-20241104_pre.xml (EX-101.PRE) — 11KB
- d872811d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 5, 2024 AN2 Therapeutics, Inc. By: /s/ Lucy O. Day Lucy O. Day Chief Financial Officer